
March 25 (Reuters) - Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that no longer responds to standard treatment.
The U.S. Food and Drug Administration approved relacorilant, brand name Lifyorli, for use in combination with the chemotherapy drug nab-paclitaxel.
The therapy is cleared for adults with platinum-resistant epithelial ovarian cancer, a type that returns or progresses within about six months of platinum-based chemotherapy.
Lifyorli works by blocking cortisol-related stress signals in the body, a mechanism that can make cancer cells more responsive to chemotherapy.
The approval was based on a late-stage trial involving 381 patients. The data showed those treated with the combination lived a median of 16 months, compared with 11.9 months for patients receiving chemotherapy alone.
Patients are advised to take 150 mg of the drug on the day before, the day of, and the day after each infusion of nab-paclitaxel, the FDA said.
The treatment carries warnings for low white blood cell counts, serious infections, adrenal insufficiency and potential harm to unborn babies, and should not be used in patients who rely on steroid medications to survive.
UBS analyst Ashwani Verma viewed the approval, which came three months ahead of schedule, as a positive, but said a contraindication for patients on steroid medications could be a hurdle and estimated its peak sales of about $550 million.
In December, the FDA had declined to approve relacorilant for hypertension linked to Cushing's syndrome, saying the drug failed to outperform a placebo and raised concerns about potential liver injury — a setback that sent the company's shares plunging about 50%.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Devika Syamnath and Shilpi Majumdar)
LATEST POSTS
- 1
The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China - 2
Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more - 3
Best Pizza Beating: What's Your #1? - 4
He walked on the moon in 1972. This is his advice for the Artemis II astronauts. - 5
Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
Bowen Yang is reportedly leaving 'Saturday Night Live' after this week's episode
4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
Popular Film Areas: A Worldwide Manual for Film Enchantment
4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
'Wicked: For Good' was filmed at this surreal National Park in Egypt
Famous Places to get-away for Americans
The Main 20 Photography Instagram Records to Follow
Famous Rough terrain Vehicles for 2024
CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year











